A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Varlilumab (Primary)
- Indications Adenocarcinoma; B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celldex Therapeutics Inc
- 11 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 02 May 2017 Results (n=56) of ealuation of patients with solid tumours, published in the Journal of Clinical Oncology
- 05 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.